Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > BUSINESS
BUSINESS
- Astellas to Transfer Kiyosu Plant Business to MicroBiopharm Japan
November 4, 2015
- Mochida Seeks Japan Approval of Ulcerative Colitis Drug
November 4, 2015
- AbbVie Files Parkinson’s Treatment in Japan
November 4, 2015
- Edoxaban Flounders in US but No Change to FY2017 Biz Targets: Daiichi Sankyo CEO
November 4, 2015
- Mitsubishi Tanabe to Cut Back on Jobs in Japan
November 4, 2015
- Mitsubishi Tanabe Sales Tick Up as Royalty Income Increases
November 4, 2015
- Daiichi Sankyo Recalls Measles, Rubella Vaccines
November 4, 2015
- Takeda Drops Development of TAK-264, TAK-272
November 2, 2015
- Sakigake Designation System Very Useful: Astellas President
November 2, 2015
- Eisai Squeezes Out Sales Rise on Growing Global Brands
November 2, 2015
- Daiichi Sankyo’s Half-Year Revenue Up 11% Due to Growth in Sales in Japan and US; Operating Profit Up 61%
November 2, 2015
- Xtandi Makes Strong Contribution to Astellas’s Half-Year Sales and Profits
November 2, 2015
- Entyvio’s Sales Jump Underpins Takeda’s Half-Year Revenue
November 2, 2015
- Shionogi Delivers Record Profits in April-September on Brisk HIV Franchise
October 30, 2015
- Sakigake Designated Anticancer Agent ASP2215 Enters Multinational PIII Study: Astellas
October 30, 2015
- Sumitomo Dainippon to Take Yet Another Stab at Lurasidone PIII for Schizophrenia
October 29, 2015
- Sumitomo Dainippon Logs Rise in Half-Year Earnings on N. America Latuda Sales, Weak Yen
October 29, 2015
- DPT-IPV Vaccine Quattrovac to Be Out of Stock in November
October 29, 2015
- Yakult Licenses Novel Platelet Increasing Agent from Nissan Chemical
October 28, 2015
- Lupin Names Fabrice Egros As President of Asia Pacific, Japan Operations
October 28, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…